[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621745":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":42,"collaborators":46,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":62,"sex":68,"minAge":69,"maxAge":10,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":82,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Peking University Shenzhen Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Treatment group",null,[12],"Drug: Iruplinalkib tablets",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Iruplinalkib tablets","180mg, QD",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"FEN WANG","CONTACT","+86 13510331485","fina_wang@163.com",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":34,"coordinates":35},"Point",[36,37],114.0683,22.54554,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":41,"phoneExt":10,"email":24},"+86 13692291485",{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Fen Wang","Associate chief physician",[47,49,51,53,55,57],{"name":48,"class":6},"Shenzhen People's Hospital",{"name":50,"class":6},"Longgang District People's Hospital of Shenzhen",{"name":52,"class":6},"Sun Yat-Sen University Cancer Center",{"name":54,"class":6},"Eighth Affiliated Hospital, Sun Yat-sen University",{"name":56,"class":6},"The First Affiliated Hospital of Guangzhou Medical University",{"name":58,"class":59},"People Hospital of New District Longhua Shenzhen","UNKNOWN","100621745","iruplinalkib-in-alk-positive-advanced-lung-adenocarcinoma-after-lorlatinib-100621745",false,"NCT07374614","Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib","An Observational Study of the Efficacy and Safety of Iruplinalkib(WX-0593) in ALK-positive Advanced Lung Adenocarcinoma Following Lorlatinib Treatment","SAILOR","Inclusion Criteria:\n\n1. Population: Male or female patients aged ≥18 years.\n2. Diagnosis: Histologically or cytologically confirmed advanced lung adenocarcinoma.\n3. Molecular Status: Documentation of ALK rearrangement confirmed by a validated test (e.g., NGS, IHC, FISH).\n4. Prior Therapy: Prior treatment with lorlatinib (in any line of therapy), with documented disease progression or intolerance.\n5. Current Therapy: Initiated treatment with iruplinalkib in the real-world setting.\n6. Measurability: Presence of at least one evaluable lesion (measurable or non-measurable) for response assessment.\n7. Data Availability: availability of key clinical data (baseline characteristics, treatment history, and follow-up outcomes).\n\nExclusion Criteria:\n\n1. Lack of Exposure: Patients who never actually received iruplinalkib or took only a trivial amount (e.g., \\\u003C 1 week\u002Fcycle) before withdrawal for non-medical reasons.\n2. Wrong Diagnosis: Active malignancy of other histological types (excluding treated basal cell carcinoma, etc.).\n3. Confounding: Participation in another interventional clinical trial involving an investigational anti-tumor drug concurrently.\n4. Pregnancy: Pregnant or breastfeeding women.\n5. Data Quality: Missing critical medical records that preclude assessment of primary endpoints (e.g., unknown start date, unknown prior therapy).","ALL","18 Years",{"count":71,"type":72},20,"ESTIMATED","OBSERVATIONAL","This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy. The results are expected to provide real-world evidence to inform clinical decision-making for this heavily pretreated patient population.",[76,77,78,79,80,81],"Non-Small Cell Lung Cancer","ALK","Iruplinalkib","Lorlatinib","Real-world Study","Observational Study",[78,83,84,85],"ALK-postive","Post-Lorlatinib","Advanced Lung Adenocarcinoma","2026-01-24",{"date":88,"type":89},"2026-01-29","ACTUAL",{"date":91,"type":72},"2026-01-31",{"date":93,"type":72},"2028-12-31",{"name":5,"class":6},1]